Figure 2.

c-Myc downregulation opens the apoptotic pathway on treatment with alkylating agents. (A) Evaluation of caspase-3 activity (upper panels, P values < .05 for MAS69 when compared to MN2 control clone following treatment with alkylating agents) and procaspase-3 expression (bottom panels) performed in the representative MN2 control clone and MAS69 c-Myc transfectant 96 hours after the end of the treatment with the IC₅₀ doses of CDDP, l-PAM, ADR, or CPT. (B) Morphological analysis of cell death performed by Hoechst staining in the representative MN2 control clone and MAS69 c-Myc transfectant 96 hours after the end of the treatment with the IC₅₀ doses of CDDP, l-PAM, ADR, or CPT. White arrows indicate apoptotic cells.